- Home
- CVKD vs RADX Comparison
CVKD vs RADX Comparison
Compare CVKD & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- RADX
- Stock Information
- Founded
- CVKD 2022
- RADX 2021
- Country
- CVKD United States
- RADX Australia
- Employees
- CVKD N/A
- RADX N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- RADX
- Sector
- CVKD Health Care
- RADX
- Exchange
- CVKD Nasdaq
- RADX NYSE
- Market Cap
- CVKD 29.5M
- RADX 32.5M
- IPO Year
- CVKD 2023
- RADX N/A
- Fundamental
- Price
- CVKD $10.54
- RADX $4.64
- Analyst Decision
- CVKD Strong Buy
- RADX Strong Buy
- Analyst Count
- CVKD 1
- RADX 3
- Target Price
- CVKD $32.00
- RADX $15.00
- AVG Volume (30 Days)
- CVKD 27.7K
- RADX 17.9K
- Earning Date
- CVKD 08-11-2025
- RADX 02-26-2025
- Dividend Yield
- CVKD N/A
- RADX N/A
- EPS Growth
- CVKD N/A
- RADX N/A
- EPS
- CVKD N/A
- RADX N/A
- Revenue
- CVKD N/A
- RADX $204,609.00
- Revenue This Year
- CVKD N/A
- RADX N/A
- Revenue Next Year
- CVKD N/A
- RADX N/A
- P/E Ratio
- CVKD N/A
- RADX N/A
- Revenue Growth
- CVKD N/A
- RADX N/A
- 52 Week Low
- CVKD $5.70
- RADX $3.50
- 52 Week High
- CVKD $22.90
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- CVKD 37.37
- RADX N/A
- Support Level
- CVKD $11.25
- RADX N/A
- Resistance Level
- CVKD $11.88
- RADX N/A
- Average True Range (ATR)
- CVKD 0.77
- RADX 0.00
- MACD
- CVKD -0.03
- RADX 0.00
- Stochastic Oscillator
- CVKD 2.95
- RADX 0.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.